GC Publishes First Sustainability Management Report... Showcasing ESG Management Achievements

[Asia Economy Reporter Lee Gwan-joo] GC (Green Cross Holdings) announced on the 25th that it has released the 'GC Sustainability Management Report 2022,' which includes the economic, environmental, social, and governance performance and plans of its major affiliates. This report is the first sustainability management report published by GC.

The report covers the company's achievements and directions related to five core focus areas for more effective ESG management: ▲creating healthcare customer value ▲corporate social responsibility ▲environmental safety and health systems ▲sustainable industrial ecosystems ▲corporate ethics and compliance.

GC and its subsidiaries conduct social contribution activities annually with voluntary participation from employees. They fulfill corporate social responsibility through donation activities such as payroll rounding donations, matching grants, and year-end donations, as well as volunteer work, support for marginalized groups, blood donations, and pharmaceutical donations.

Additionally, GC Green Cross has switched from using liquefied natural gas (LNG) fuel at its Ochang plant since 2017 to externally supplied steam (heat) to reduce greenhouse gas emissions and save energy. This transition reduces fossil fuel-based energy consumption and suppresses nitrogen oxide (NOx) emissions. Since 2018, the company has introduced the Energy Storage System (ESS), an energy-smart technology, to improve electricity usage efficiency.

GC continues to focus on developing and supplying treatments for rare and intractable diseases, an unexplored field. GC Green Cross succeeded in developing 'Hunterase,' the world's second treatment for Hunter syndrome, and was the first in the world to commercialize a treatment for severe Hunter syndrome patients. Furthermore, by obtaining Chinese approval for its domestically developed recombinant gene therapy for hemophilia, 'GreenGene F,' the company strives to provide new treatment options for patients with difficult-to-treat conditions. GC Cell (GC Cell) is also conducting ongoing research to expand indications of existing commercialized products or develop new therapies for cancers that are difficult to treat and have low survival rates.

A GC official stated, “We plan to publish a sustainability management report annually, including ESG performance and plans, to ensure transparent communication with various stakeholders.”

This content was produced with the assistance of AI translation services.